Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers

Clinical Genetics

Volumn 85, Issue 1, 2014, Pages 49-53

  Pal, T ^a   Lee, J H ^a   Besharat, A ^a   Thompson, Z ^a   Monteiro, A N A ^a   Phelan, C ^a   Lancaster, J M ^a   Metcalfe, K ^b   Sellers, T A ^a   Vadaparampil, S ^a   Narod, S A ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA; Clinical practice delivery; Genetic counseling; Genetic testing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HEALTH CARE DELIVERY; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUESTIONNAIRE; RISK MANAGEMENT;

BRCA; CLINICAL PRACTICE DELIVERY; GENETIC COUNSELING; GENETIC TESTING;

ADULT; AGED; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PREMEDICATION; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; TAMOXIFEN; YOUNG ADULT;

EID: 84890167860     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12130     Document Type: Article

References (13)

1. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994: 266 (5182): 66-71.
2. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995: 378 (6559): 789-792.
3. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005: 23 (8): 1656-1663.
4. Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012: 19 (4): 255-266.
5. Genetic/Familial High-risk Assessment: Breast and Ovarian. In: NCCN Practice Guidelies. V.3.2011 ed. Fort Washington, PA: National Comprehensive Cancer Network, 2012.
6. Riley BD, Culver JO, Skrzynia C et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012: 21 (2): 151-161.
7. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010: 28 (5): 893-901.
8. Stuckey A, Dizon D, Scalia Wilbur J et al. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest 2010: 69 (4): 270-273.
9. Dhar SU, Cooper HP, Wang T et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 2011: 129 (1): 221-227.
10. Keating NL, Stoeckert KA, Regan MM, Di Gianni L, Garber JE. Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol 2008: 26 (35): 5789-5796.
11. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011: 61: 327-359.
12. Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 2005: 42 (10): 749-755.
13. Brierley KL, Blouch E, Cogswell W et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J 2012: 18 (4): 303-309.